bioAffinity Technologies Hits New 52-Week Low at $1.91

bioAffinity Technologies, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.91 on November 7, 2025. This significant drop highlights the company's ongoing struggles, as it has experienced a 1-year performance decline of 8.85%, contrasting sharply with the S&P 500's gain of 12.65% during the same period.
The company's market capitalization stands at USD 7 million, reflecting its microcap status. bioAffinity Technologies has faced challenges in generating positive financial metrics, with a negative operating cash flow of USD -7.68 million and a return on capital employed (ROCE) of -1,802.45%. Additionally, the company has reported a staggering annual growth rate of -223.18% in operating profit over the last five years, indicating persistent financial difficulties.

With a price-to-book ratio of -3.27 and a debt-to-equity ratio of 0.19, bioAffinity Technologies continues to navigate a challenging financial landscape. The stock's performance has been notably poor, generating a return of -94.80% over the past year, further emphasizing the need for a reassessment of its operational strategies.